Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.58 million versus the consensus estimate of $3.33 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.